Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.1 USD | -0.24% | +4.33% | +10.91% |
05-09 | NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-08 | Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target | MT |
Business Summary
Number of employees: 8
Managers
Managers | Title | Age | Since |
---|---|---|---|
Hyung-Heon Kim
CEO | Chief Executive Officer | 47 | 21-07-08 |
Director of Finance/CFO | 66 | 23-10-26 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
D. Strickland
BRD | Director/Board Member | 77 | 22-01-26 |
Andrew Koven
CHM | Chairman | 66 | 21-07-08 |
Mark Glickman
BRD | Director/Board Member | 58 | 23-05-10 |
Michael Salsbury
BRD | Director/Board Member | 74 | 19-12-30 |
Jason Groves
BRD | Director/Board Member | 52 | 19-12-30 |
James Tursi
BRD | Director/Board Member | 59 | 10-31 |
Hyung-Heon Kim
CEO | Chief Executive Officer | 47 | 21-07-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 4,906,002 | 1,880,689 ( 38.33 %) | 0 | 38.33 % |
Company contact information
NeuroBo Pharmaceuticals, Inc.
545 Concord Avenue Suite 210
02138, Cambridge
+
http://www.neurobopharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.91% | 20.16M | |
+7.59% | 111B | |
+11.31% | 106B | |
-12.22% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-9.01% | 16.81B | |
+38.67% | 12.54B | |
-24.41% | 8.09B |
- Stock Market
- Equities
- NRBO Stock
- Company NeuroBo Pharmaceuticals, Inc.